DOCSLIB.ORG

Understanding, Diagnosing, and Treating Neurotrophic Keratitis in 2020 Release Date: August 2020 Expiration Date: September 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Understanding, Diagnosing, and Treating Neurotrophic Keratitis in 2020 Release Date: August 2020 Expiration Date: September 2021 Supplement to September 2020 Francis S. Mah, MD Marjan Farid, MD UNDERSTANDING, Stephen C. Pflugfelder, MD DIAGNOSING, Karolinne Maia Rocha, MD, PhD AND TREATING NEUROTROPHIC KERATITIS IN 2020 Distributed with Provided by A CME activity provided by Evolve Medical Education LLC This activity is supported by an independent medical education grant from Dompé. Understanding, Diagnosing, and Treating Neurotrophic Keratitis in 2020 Release Date: August 2020 Expiration Date: September 2021 FACULTY FRANCIS S. MAH, MD MARJAN FARID, MD STEPHEN C. KAROLINNE MAIA ROCHA, Program Moderator Professor of Ophthalmology PFLUGFELDER, MD MD, PHD Director, Cornea and External Disease School of Medicine Professor of Ophthalmology Director, Cornea & Refractive Surgery Co-Director, Refractive Surgery Vice Chair, Ophthalmic Faculty James and Margaret Elkins Chair Storm Eye Institute Scripps Clinic Director, Cornea/External Disease, Director, Ocular Surface Center Baylor Medical University of South Carolina La Jolla, CA Cataract, and Refractive Surgery College of Medicine Charleston, SC Gavin Herbert Eye Institute Houston, TX University of California, Irvine Irvine, CA CONTENT SOURCE • Recognize the various potential causes of neurotrophic This continuing medical education (CME) activity captures keratitis and when referrals may be necessary. content from two webcasts. • Summarize mechanisms of action of newer treatments and when they should be introduced into treatment regimens ACTIVITY DESCRIPTION for neurotrophic keratitis. Eye care providers may not understand what neurotrophic • Identify the relationships between disease characteristics, keratitis is or how it differs from other corneal diseases. In drug, treatment frequency, visual, and anatomic outcomes. addition; eye care practitioners may be unaware of treatments in development, or the already approved treatments for GRANTOR STATEMENT neurotrophic keratitis. They also may not understand This activity is supported through an educational grant from the mechanism of action of these newer treatments. This Dompé. supplement features four experts in neurotrophic keratitis who review important issues related to managing patients, ACCREDITATION STATEMENT including the scope and causes of the disease, comorbid Evolve Medical Education LLC (Evolve) is accredited by systemic conditions, ocular exam, and corneal sensation. the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. TARGET AUDIENCE This certified CME activity is designed for anterior segment CREDIT DESIGNATION STATEMENT specialists, general ophthalmologists, and other eye care Evolve designates this enduring material for a maximum of providers involved in the management of corneal disorders. 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in LEARNING OBJECTIVES the activity. Upon completion of this activity, the participant should be able to: • Describe the stages of neurotrophic keratitis and how to differentiate it from similar diseases. 2 SUPPLEMENT TO CATARACT & REFRACTIVE SURGERY TODAY | SEPTEMBER 2020 TO OBTAIN CREDIT Stephen C. Pflugfelder, MD, and/or spouse/partner has had To obtain credit for this activity, you must read the activity a financial agreement or affiliation during the past year with in its entirety and complete the Pretest/Posttest/Activity the following commercial interests in the form of Consultant: Evaluation/Satisfaction Measures Form, which consists of a series Allergan and Kala. Grant/Research Support: Allergan. of multiple choice questions. To answer these questions online and receive real-time results, please visit http://evolvemeded. Karolinne Maia Rocha, MD, PhD, and/or spouse/partner has com/online-courses/2010-supplement. Upon completing the had a financial agreement or affiliation during the past year with activity and self-assessment test, you may print a CME credit the following commercial interests in the form of Consultant: letter awarding 1 AMA PRA Category 1 Credit™. Alternatively, Ace Vision, Alcon, Allergan, Avedro, Bausch + Lomb, Dompé, please complete the Posttest/Activity Evaluation/Satisfaction and Johnson & Johnson Vision. Form and mail or fax to Evolve Medical Education LLC, 353 West Lancaster Avenue, Second Floor, Wayne, PA 19087; EDITORIAL SUPPORT DISCLOSURES Fax: (215) 933-3950. The Evolve staff and planners have no financial relationships with commercial interests. Virginia Pickles, writer, and Nisha DISCLOSURE POLICY Mukherjee, MD, peer reviewer, have no financial relationships It is the policy of Evolve that faculty and other individuals with commercial interests. who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to OFF-LABEL STATEMENT the topics of this educational activity. Evolve has full policies in This educational activity may contain discussion of published place that will identify and resolve all conflicts of interest prior and/or investigational uses of agents that are not indicated by to this educational activity. the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing The following faculty/staff members have the following information for each product for discussion of approved financial relationships with commercial interests: indications, contraindications, and warnings. Marjan Farid, MD, and/or spouse/partner has had a financial DISCLAIMER agreement or affiliation during the past year with the following The views and opinions expressed in this educational activity commercial interests in the form of Consultant: Allergan, Biotissue, are those of the faculty and do not necessarily represent the CorneaGen, Dompé, Johnson & Johnson Vision, and Novartis. views of Evolve, Cataract & Refractive Surgery Today, or Dompé. Francis S. Mah, MD, and/or spouse/partner has had a financial DIGITAL EDITION agreement or affiliation during the past year with the follow- To view the online version of the material, please go to ing commercial interests in the form of Consultant and Speaker’s http://evolvemeded.com/online-courses/2010-supplement. Bureau: Dompé. SEPTEMBER 2020 | SUPPLEMENT TO CATARACT & REFRACTIVE SURGERY TODAY 3 PLEASE COMPLETE PRIOR TO ACCESSING THE MATERIAL AND SUBMIT WITH POSTTEST/ACTIVITY EVALUATION/SATISFACTION MEASURES INSTRUCTIONS FOR CME CREDIT. 1. Please rate your confidence in your ability to identify and treat patients 7. To which stage of neurotrophic keratitis does the following with neurotrophic keratitis (based on a scale of 1 to 5, with 1 = “Not at all description apply: “Persistent epithelial defect with smooth rolled edges; confident” and 5= “Very confident”). stromal opacity”? a. 1 a. Stage 1 b. 2 b. Stage 2 c. 3 c. Stage 3 d. 4 e. 5 8. Which of the following is an appropriate therapy for stage 3 neurotrophic keratitis? 2. A 53-year-old woman with a diagnosis of neurotrophic keratitis presents a. Recombinant human nerve growth factor to your office. Which of the following are reasonable options for treatment b. Preservative free artificial tears (more than one may apply)? c. Punctal occlusion a. Artificial tears d. Hydrogel contact lens b. Topical Ointment c. Latanoprost topical drops 9. A 67-year-old female with a nonhealing corneal epithelial defect d. Cenegermin presents to your office. She has a history of bilateral LASIK and herpes zoster ophthalmicus. She has previously attempted amniotic membrane 3. What is the most common etiology of neurotrophic keratitis? allograft, bandage contact lens, and autologous serum tears for a. Postsurgical damage to ciliary nerves treatment, yet her persistent epithelial defect remains. Which of the b. Postherpetic infections following is an appropriate treatment for this patient? c. Diabetes mellitus a. Start cenegermin 20 mcg/mL d. Corneal dystrophies b. Punctal occlusion c. Preservative free artificial tears 4. What is the hallmark finding of neurotrophic keratitis? a. Punctate epithelial erosions 10. In the cenegermin clinical trials, what was the most common b. Abnormal Schirmer test adverse reaction? c. Abnormal corneal sensitivity testing a. Eye irritation d. Lid laxity b. Red eye c. Eye pain following instillation 5. A 72-year-old man with primary open-angle glaucoma presents with blurry vision. On exam, he has an epithelial defect with rolled edges. 11. A 40-year-old male with a history of diabetes and bilateral LASIK He has decreased corneal sensitivity. Which of the following made him OU presents with diffuse punctate epitheliopathy, decreased tear at risk for this diagnosis (more than one may apply)? break-up time, and stromal haze. Which of the following is an appropriate a. Use of multiple topical glaucoma medications treatment for this patient? b. Blepharitis a. Scleral lens c. His age b. Preservative free artificial tears d. History of glaucoma c. Amniotic membrane d. Tarsorrhaphy 6. Which of the following is an example of a quantitative corneal sensitivity test? a. Cochet-Bonnet esthesiometer b. Cotton swab c. Dental floss 4 SUPPLEMENT TO CATARACT & REFRACTIVE SURGERY TODAY | SEPTEMBER 2020 UNDERSTANDING, DIAGNOSING, AND TREATING NEUROTROPHIC KERATITIS IN 2020 Understanding, Diagnosing, and Treating Neurotrophic Keratitis in 2020 BREAKING THE CYCLE OF RECURRENCE Novel recombinant human nerve growth factor heals persistent epithelial defects. BY FRANCIS S. MAH, MD eurotrophic keratitis is a rare, degenerative disease of
Load more

Recommended publications
  • Summary Benchmarks for Preferred Practice Pattern® Guidelines
    SUMMARY BENCHMARKS FOR PREFERRED PRACTICE PATTERN® GUIDELINES TABLE OF CONTENTS Summary Benchmarks for Preferred Practice Pattern Guidelines Introduction . 1 Glaucoma Primary Open-Angle Glaucoma (Initial Evaluation) . 3 Primary Open-Angle Glaucoma (Follow-up Evaluation) . 5 Primary Open-Angle Glaucoma Suspect (Initial and Follow-up Evaluation) . 6 Primary Angle-Closure Disease (Initial Evaluation and Therapy) . 8 Retina Age-Related Macular Degeneration (Initial and Follow-up Evaluation) . 10 Age-Related Macular Degeneration (Management Recommendations) . 11 Diabetic Retinopathy (Initial and Follow-up Evaluation) . 12 Diabetic Retinopathy (Management Recommendations) . 13 Idiopathic Epiretinal Membrane and Vitreomacular Traction (Initial Evaluation and Therapy) . 14 Idiopathic Macular Hole (Initial Evaluation and Therapy) . 15 Posterior Vitreous Detachment, Retinal Breaks, and Lattice Degeneration (Initial and Follow-up Evaluation) . 17 Retinal and Ophthalmic Artery Occlusions (Initial Evaluation and Therapy) . 18 Retinal Vein Occlusions (Initial Evaluation and Therapy) . 19 Cataract/Anterior Segment Cataract (Initial and Follow-up Evaluation) . 20 Cornea/External Disease Bacterial Keratitis (Initial Evaluation) . 22 Bacterial Keratitis (Management Recommendations) . 23 Blepharitis (Initial and Follow-up Evaluation) . 24 Conjunctivitis (Initial Evaluation) . 25 Conjunctivitis (Management Recommendations) . 26 Corneal Ectasia (Initial Evaluation and Follow-up) . 27 Corneal Edema and Opacification (Initial Evaluation) . 28 Corneal Edema
    [Show full text]
  • Corneal Changes in Neurosurgically Induced Neurotrophic Keratitis
    Research Original Investigation | CLINICAL SCIENCES Corneal Changes in Neurosurgically Induced Neurotrophic Keratitis Alessandro Lambiase, MD, PhD; Marta Sacchetti, MD, PhD; Alessandra Mastropasqua, MD; Stefano Bonini, MD IMPORTANCE Neurotrophic keratitis (NK) represents a sight-threatening complication after trigeminal impairment. To our knowledge, the duration for which trigeminal injury may affect corneal structures and function has not been investigated previously. OBJECTIVE To describe the long-term clinical, morphological, and functional outcomes of NK after neurosurgical trigeminal damage. DESIGN, SETTING, AND PARTICIPANTS Observational case series performed at a corneal and ocular surface diseases referral center in 2010. Eight consecutive patients with monolateral NK from 1 to 19 years after neurosurgery and 20 age- and sex-matched healthy participants were included. MAIN OUTCOMES AND MEASURES Complete eye examination, tear film function tests, corneal staining, and Cochet-Bonnet esthesiometry were performed. The number and density of corneal nerves, number of hyperreflective keratocytes, and corneal epithelial, endothelial, and keratocyte cell densities were evaluated by in vivo slit scanning confocal microscopy. Clinical and morphological data were compared with the contralateral unaffected eyes and with the eyes of healthy control participants. RESULTS All patients showed superficial punctate keratitis and dry eye in the NK eye and a healthy contralateral eye. Decreased corneal sensitivity was observed in all affected eyes (mean [SD], 2.0 [1.9] mm in the affected eyes vs 5.8 [0.3] mm in the contralateral unaffected eyes; P = .01) and was related to decreased subbasal nerve length (P = .04; R = 0.895). Corneal epithelial and endothelial cell densities were significantly decreased and the number of hyperreflective keratocytes was significantly increased in NK eyes compared with contralateral unaffected eyes and with the eyes of healthy participants.
    [Show full text]
  • Ophthalmic Herpes Zoster
    OPHTHALMIC HERPES ZOSTER RONALD J. MARSH and MATTHEW COOPER London SUMMARY Fig. 1 shows the age and sex distribution, which is A current review of ophthalmic zoster is presented biased in favour of females and compares with 50.7% including its virology, immunology, epidemiology and males, 49.3% females in another series.5 The 1981 census pathogenesis. We give our findings in 1356 patients for Greater London recorded 48% males and 52% referred to the Zoster Clinic at Moorfields Ey e Hospital, females. London. The treatment of the disease and its ocular com­ ONSET plications is discussed. There is a prodromal influenza-like illness of varying Ophthalmic herpes zoster is a disease varying in severity duration, with headache, pyrexia, malaise, depression, and from devastating, threatening life and sight, to so mild that sometimes neck stiffness, which may last up to a week it may pass unnoticed. The ophthalmic division of the fifth before the rash appears. This is shortly followed by local­ cranial nerve is affected in 7-17.5% of herpes zoster ised pain over the distribution of the ophthalmic nerve, patients. 1-5 Ocular involvement complicates approxi­ lymph node swelling in the corresponding drainage areas mately 50% of these cases and very rarely cases of maxil­ and, occasionally, a red eye. The localised pain is well lary herpes zoster,l affecting many of the tissues of the known to precede the rash by several days in some cases. globe and orbit by highly varied types of lesions. This probably represents the replication and migration We felt it would be helpful to report our experience with phase of the disease and is possibly accompanied by a lim­ the disease because the large number of cases we have ited viraemia.
    [Show full text]
  • Description of Alternative Approaches to Measure and Place a Value on Hospital Products in Seven Oecd Countries
    OECD Health Working Papers No. 56 Description of Alternative Approaches to Measure Luca Lorenzoni, and Place a Value Mark Pearson on Hospital Products in Seven OECD Countries https://dx.doi.org/10.1787/5kgdt91bpq24-en Unclassified DELSA/HEA/WD/HWP(2011)2 Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development 14-Apr-2011 ___________________________________________________________________________________________ _____________ English text only DIRECTORATE FOR EMPLOYMENT, LABOUR AND SOCIAL AFFAIRS HEALTH COMMITTEE Unclassified DELSA/HEA/WD/HWP(2011)2 Health Working Papers OECD HEALTH WORKING PAPERS NO. 56 DESCRIPTION OF ALTERNATIVE APPROACHES TO MEASURE AND PLACE A VALUE ON HOSPITAL PRODUCTS IN SEVEN OECD COUNTRIES Luca Lorenzoni and Mark Pearson JEL Classification: H51, I12, and I19 English text only JT03300281 Document complet disponible sur OLIS dans son format d'origine Complete document available on OLIS in its original format DELSA/HEA/WD/HWP(2011)2 DIRECTORATE FOR EMPLOYMENT, LABOUR AND SOCIAL AFFAIRS www.oecd.org/els OECD HEALTH WORKING PAPERS http://www.oecd.org/els/health/workingpapers This series is designed to make available to a wider readership health studies prepared for use within the OECD. Authorship is usually collective, but principal writers are named. The papers are generally available only in their original language – English or French – with a summary in the other. Comment on the series is welcome, and should be sent to the Directorate for Employment, Labour and Social Affairs, 2, rue André-Pascal, 75775 PARIS CEDEX 16, France. The opinions expressed and arguments employed here are the responsibility of the author(s) and do not necessarily reflect those of the OECD.
    [Show full text]
  • National Correct Coding Initiative's (Ncci) General
    NATIONAL CORRECT CODING INITIATIVE’S (NCCI) GENERAL CORRESPONDENCE LANGUAGE AND SECTION-SPECIFIC EXAMPLES (FOR NCCI PROCEDURE TO PROCEDURE (PTP) EDITS AND MEDICALLY UNLIKELY EDITS (MUE)) EFFECTIVE: April 1, 2017* *INCLUDES 2017 HCPCS/CPT CODES Current Procedural Terminology (CPT) codes, descriptions and other data only are copyright 2016 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association. Applicable FARS\DFARS Restrictions Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for the data contained or not contained herein. TABLE OF CONTENTS Section Page Introduction 5 General Correspondence Language for NCCI PTP Edits and Medically Unlikely Edits (MUEs) Standard preparation/monitoring services for anesthesia 8 HCPCS/CPT procedure code definition 8 CPT Manual or CMS manual coding instruction 8 Mutually exclusive procedures 9 Sequential procedure 9 CPT “Separate procedure” definition 9 More extensive procedure 9 Gender-specific procedures 10 Standards of medical/surgical practice 10 Anesthesia service included in surgical procedure 10 Laboratory panel 10 Deleted/modified edits for NCCI 11 Misuse of column two code with column one code 11 Medically Unlikely Edits (MUE) (Units of Service) 11 Deleted/modified edits
    [Show full text]
  • Retinal Pigment Epithelial Tear Resembling Retinal Tear
    Correspondence 333 References 5University of Washington/Fred Hutchinson 1 Dean WH, Banda L, Kambewa ES, Sherwin JC. Increased Cancer Research Center, Seattle, WA, USA intraocular pressure on the first post-operative day 6Department of Ophthalmology and Visual following sutureless extracapsular cataract surgery in Sciences, The University of Texas Medical Branch, Africa. Eye 2012; 26: 332. Galveston, TX, USA 2 Kim JY, Jo MW, Brauner SC, Ferrufino-Ponce Z, Ali R, 7Ophthalmic Consultants of Boston, Harvard Cremers SL et al. Increased intraocular pressure on the first Medical School, Boston, MA, USA postoperative day following resident-performed cataract E-mail: [email protected] surgery. Eye (Lond) 2011; 25: 929–936. Eye (2012) 26, 332–333; doi:10.1038/eye.2011.274; JY Kim1,2,3, M-W Jo4, SC Brauner3, Z Ferrufino-Ponce5, published online 11 November 2011 R Ali6, SL Cremers3 and BA Henderson7 1Department of Ophthalmology, University of Sir, Ulsan College of Medicine, Asan Medical Center, Retinal pigment epithelial tear resembling retinal Seoul, Republic of Korea tear 2Research Institute for Biomacromolecules, University of Ulsan College of Medicine, Case report Asan Medical Center, Seoul, Republic of Korea A 74-year-old Caucasian female with history of advanced 3Massachusetts Eye and Ear Infirmary, Harvard age-related macular degeneration presented with Medical School, Boston, MA, USA decreased vision in the right eye. The patient was 4Department of Preventive Medicine, University of treated with two ranibizumab injections for choroidal Ulsan College of Medicine, Seoul, Republic of Korea neovascularization 5 months prior without Figure 1 (a) SD-OCT showing RPE defect with overlying intact retina.
    [Show full text]
  • Diagnosis and Treatment of Neurotrophic Keratopathy
    An Evidence-based Approach to the Diagnosis and Treatment of Neurotrophic Keratopathy ACTIVITY DIRECTOR A CME MONOGRAPH Esen K. Akpek, MD This monograph was published by Johns Hopkins School of Medicine in partnership Wilmer Eye Institute with Catalyst Medical Education, LLC. It is Johns Hopkins School of Medicine not affiliated with JAMA medical research Baltimore, Maryland publishing. Visit catalystmeded.com/NK for online testing to earn your CME credit. FACULTY Natalie Afshari, MD Mina Massaro-Giordano, MD Shiley Eye Institute University of Pennsylvania School of Medicine University of California, San Diego Philadelphia, Pennsylvania La Jolla, California Nakul Shekhawat, MD, MPH Sumayya Ahmad, MD Wilmer Eye Institute Mount Sinai School of Medicine Johns Hopkins School of Medicine New York, New York Baltimore, Maryland Pedram Hamrah, MD, FRCS, FARVO Christopher E. Starr, MD Tufts University School of Medicine Weill Cornell Medical College Boston, Massachusetts New York, New York ACTIVITY DIRECTOR FACULTY Esen K. Akpek, MD Natalie Afshari, MD Mina Massaro-Giordano, MD Professor of Ophthalmology Professor of Ophthalmology Professor of Clinical Ophthalmology Director, Ocular Surface Diseases Chief of Cornea and Refractive Surgery University of Pennsylvania School and Dry Eye Clinic Vice Chair of Education of Medicine Wilmer Eye Institute Fellowship Program Director of Cornea Philadelphia, Pennsylvania Johns Hopkins School of Medicine and Refractive Surgery Baltimore, Maryland Shiley Eye Institute Nakul Shekhawat, MD, MPH University of California,
    [Show full text]
  • Herpetic Corneal Infections
    FocalPoints Clinical Modules for Ophthalmologists VOLUME XXVI, NUMBER 8 SEPTEMBER 2008 (MODULE 2 OF 3) Herpetic Corneal Infections Sonal S. Tuli, MD Reviewers and Contributing Editors Consultants George A. Stern, MD, Editor for Cornea & External Disease James Chodosh, MD, MPH Kristin M. Hammersmith, MD, Basic and Clinical Science Course Faculty, Section 8 Kirk R. Wilhelmus, MD, PhD Christie Morse, MD, Practicing Ophthalmologists Advisory Committee for Education Focal Points Editorial Review Board George A. Stern, MD, Missoula, MT Claiming CME Credit Editor in Chief, Cornea & External Disease Thomas L. Beardsley, MD, Asheville, NC Academy members: To claim Focal Points CME cred- Cataract its, visit the Academy web site and access CME Central (http://www.aao.org/education/cme) to view and print William S. Clifford, MD, Garden City, KS Glaucoma Surgery; Liaison for Practicing Ophthalmologists Advisory your Academy transcript and report CME credit you Committee for Education have earned. You can claim up to two AMA PRA Cate- gory 1 Credits™ per module. This will give you a maxi- Bradley S. Foster, MD, Springfield, MA Retina & Vitreous mum of 24 credits for the 2008 subscription year. CME credit may be claimed for up to three (3) years from Anil D. Patel, MD, Oklahoma City, OK date of issue. Non-Academy members: For assistance Neuro-Ophthalmology please send an e-mail to [email protected] or a Eric P. Purdy, MD, Fort Wayne, IN fax to (415) 561-8575. Oculoplastic, Lacrimal, & Orbital Surgery Steven I. Rosenfeld, MD, FACS, Delray Beach, FL Refractive Surgery, Optics & Refraction C. Gail Summers, MD, Minneapolis, MN Focal Points (ISSN 0891-8260) is published quarterly by the American Academy of Ophthalmology at 655 Beach St., San Francisco, CA 94109-1336.
    [Show full text]
  • Anterior Segment Surgery and Complications CATARACT EXTRACTION and INTRAOCULAR LENS IMPLANTATION
    10 Anterior Segment Surgery and Complications CATARACT EXTRACTION AND INTRAOCULAR LENS IMPLANTATION Complications PENETRATING KERATOPLASTY Complications Correction of Astigmatism in a Corneal Graft LAMELLAR KERATOPLASTY SUPERFICIAL KERATECTOMY EXCIMER LASER PHOTOTHERAPEUTIC KERATECTOMY CONJUNCTIVAL FLAP LIMBAL STEM CELL TRANSPLANTATION PTERYGIUM EXCISION AND CONJUNCTIVAL AUTOGRAFT CONJUNCTIVAL AND CORNEAL TUMOR EXCISION CORNEAL PERFORATION SURGERY PERMANENT KERATOPROSTHESIS REFRACTIVE SURGERY Radial Keratotomy Excimer Laser Photorefractive Keratectomy Laser In Situ Keratomileusis CONCLUSION Anterior segment surgery ranges from routine cataract extraction and lens implantation, one of the most common surgical operations in the United States, to rarely performed surgery such as permanent keratoprosthesis. It also encompasses surgery first performed centuries ago, such as rudimentary pterygium excision, to the latest in keratorefractive surgery. CATARACT EXTRACTION AND INTRAOCULAR LENS IMPLANTATION The many reasons for the development of cataracts are discussed in detail in Chapter 8. Most cataracts are acquired, but they can also be congenital. This section focuses primarily on the treatment of acquired cataracts in adults. Cataracts in adults are generally age related, but some lens opacities may result from other causes such as trauma, inflammation, systemic illness such as diabetes, or medications such as corticosteroids. Cataracts generally advance slowly over years but can advance rapidly over months, or even faster in some patients. The primary indication for cataract extraction is diminished vision caused by the cataract, significantly affecting the patient's lifestyle. The exact point at which this hardship occurs depends on the patient. Certain patients require little visual function and may delay cataract surgery for years or indefinitely. Other patients with high visual needs seek cataract surgery with much smaller degrees of visual loss.
    [Show full text]
  • Herpes Zoster Ophthalmicus—Diagnosis and Management
    Herpes Zoster Ophthalmicus—Diagnosis and Management Antoine Rousseau, MD1, Tristan Bourcier, MD PhD2, Joseph Colin, MD, PhD3, Marc Labetoulle, MD PhD4 1 Ophthalmologist, Ophthalmology Department, Bicêtre Hospital, South Paris University, Le Kremlin-Bicêtre, France, 2. Head, Ophthalmology Department, Nouvel Hôpital Civil, Strasbourg University Hospital, Strasbourg, France, 3. Head, Ophthalmology Department, Bordeaux University Hospital, Bordeaux, France, 4. Head, Ophthalmology Department, Bicêtre Hospital, South Paris University, Le Kremlin-Bicêtre, France, and Herpes Team leader, laboratory of molecular and structural virology, National Center for the Scientific Research, Gif-Sur-Yvette, France. Abstract Varicella-zoster virus (VZV) infections are widely distributed in the general population. The lifetime risk of herpes zoster is estimated to be 10–20 %, increasing with age (1–4). Since herpes zoster ophthalmicus (HZO) accounts for 20 % of all locations of shingles, the lifetime risk of HZO is about 1–2 %. The management of ocular complications of VZV infection is now well codified, but sequellae still can occur, despite an armamentarium effective in limiting viral replication and its immune consequences. Keywords Herpes zoster ophtalmicus (HZO), keratitis, post herpetic neuralgia Disclosure: The authors have no conflicts of interest to declare. Received: November 18, 2012 Accepted: December 20, 2012 Citation: US Ophthalmic Review, 2013; 6(2):[ePub ahead of print] DOI: 10.17925/USOR.2013.06.02.1 Correspondence: Pr Marc Labetoulle, Service d’Ophtalmologie, CHU de Bicêtre, Assistance Publique – Hôpitaux de Paris, Université Paris-Sud, 94275 Le Kremlin-Bicêtre, France E: [email protected] Pathophysiology: The three Phases of Varicella sites of latency for VZV, the sensory neurons of the trigeminal and spinal Zoster Virus Infection sensory ganglia seem particularly concerned.7 The Primary Infection This mostly occurs during childhood and early years of adult life.
    [Show full text]
  • Role of Temporary Tarsorrhaphy Using Super Glue in the Management of Corneal Disorders
    Original Article Role of Temporary Tarsorrhaphy Using Super Glue in the Management of Corneal Disorders Muhammad Moin, Irfan Qayyum, Anwar Ul-Haq Ahmad, Mumtaz Hussain Pak J Ophthalmol 2009, Vol. 25 No. 3 . .. .. See end of article for Purpose: To evaluate the safety and efficacy of temporary tarsorrhaphy using authors affiliations super glue in the management of corneal disorders. … ……………………… Material and Methods: A retrospective chart review of 46 consecutive patients who underwent superglue tarsorrhaphy from June 1997 to June 1998 was Correspondence to: performed. All patients were managed at the Institute of Ophthalmology, Mayo Mohammad Moin hospital, Lahore. This study included patients with painful non healing corneal Department of Ophthalmology ulcers, exposure keratopathy (secondary to moderate proptosis), dry eyes (to Mayo Hospital reduce surface area of evaporation) and post-operative patients with conjunctival Lahore flaps ± scleral grafts (to help take up of the graft). Patients with corneal perforations, endopthalmitis or panophthalmitis were excluded from the study. Temporary tarsorrhaphy was done using super glue technique in which the upper eyelashes were glued to the lower lid skin. The degree of lid closure was calculated according to the pre-existing corneal pathology. Patients were followed up on a weekly basis for one month to check for reduction of pain, improvement of corneal pathology and duration of tarsorrhaphy. Results: There were 50 eyes of 46 patients included in the study who underwent super glue tarsorrhaphy for various corneal pathologies. There were 36 males and 10 female patients with an average age of 40 years (range 10-60 yrs). Thirty two eyes had keratitis (fungal, bacterial, disciform, dendritic), 5 had a persistent epithelial defect, 4 had exposure keratopathy secondary to moderate proptosis, 5 had conjunctival flap alone or combined with a scleral graft and 4 had dry eyes.
    [Show full text]
  • Refractive Management/Intervention 2017-2019
    Academy MOC Essentials® Practicing Ophthalmologists Curriculum 2017–2019 Refractive Management/Intervention *** Refractive Management/Intervention 2 © AAO 2017-2019 Practicing Ophthalmologists Curriculum Disclaimer and Limitation of Liability As a service to its members and American Board of Ophthalmology (ABO) diplomates, the American Academy of Ophthalmology has developed the Practicing Ophthalmologists Curriculum (POC) as a tool for members to prepare for the Maintenance of Certification (MOC) -related examinations. The Academy provides this material for educational purposes only. The POC should not be deemed inclusive of all proper methods of care or exclusive of other methods of care reasonably directed at obtaining the best results. The physician must make the ultimate judgment about the propriety of the care of a particular patient in light of all the circumstances presented by that patient. The Academy specifically disclaims any and all liability for injury or other damages of any kind, from negligence or otherwise, for any and all claims that may arise out of the use of any information contained herein. References to certain drugs, instruments, and other products in the POC are made for illustrative purposes only and are not intended to constitute an endorsement of such. Such material may include information on applications that are not considered community standard, that reflect indications not included in approved FDA labeling, or that are approved for use only in restricted research settings. The FDA has stated that it is the responsibility of the physician to determine the FDA status of each drug or device he or she wishes to use, and to use them with appropriate patient consent in compliance with applicable law.
    [Show full text]